Table 1.
Comparison of clinical characteristics based on YTHDF1 and YTHDF2 expression in the tumor
| YTHDF1 |
YTHDF2 |
||||||
|---|---|---|---|---|---|---|---|
| Total | Low | High | Low | High | |||
| N = 603 | N = 291 | N = 312 | P-value | N = 404 | N = 199 | P-value | |
| Age | |||||||
| Mean, (range) | 68 (23–88) | 68 (23–88) | 68 (39–88) | N.S. | 68 (23–88) | 68 (33–88) | N.S. |
| Sex, n, (%) | |||||||
| Male | 414 (68.7) | 205 (70.4) | 209 (67.0) | N.S. | 283 (70.0) | 131 (65.8) | N.S. |
| Female | 189 (31.3) | 86 (29.6) | 103 (33.0) | 121 (33.0) | 68 (34.2) | ||
| Smoking status, n, (%) | |||||||
| Never | 179 (29.7) | 79 (27.1) | 100 (32.1) | N.S. | 115 (28.5) | 64 (32.2) | N.S. |
| Ever | 411 (68.2) | 204 (70.1) | 207 (66.3) | 277 (68.6) | 134 (67.3) | ||
| Unknown | 13 (2.1) | 8 (2.7) | 5 (1.6) | 12 (3.0) | 1 (0.5) | ||
| Histology, n, (%) | |||||||
| Adenocarcinoma | 392 (65.0) | 171 (58.8) | 221 (70.8) | .007 | 250 (61.9) | 142 (71.4) | .012 |
| Squamous cell carcinoma | 170 (27.0) | 98 (33.7) | 72 (23.1) | 129 (32.0) | 41 (20.6) | ||
| Others | 41 (68.0) | 22 (7.6) | 19 (6.1) | 25 (6.2) | 16 (8.0) | ||
| Tumor status, n, (%) | |||||||
| 1 | 236 (39.1) | 106 (36.4) | 130 (45.2) | N.S. | 148 (36.6) | 88 (44.2) | N.S. |
| 2 | 267 (44.3) | 126 (43.3) | 141 (45.2) | 186 (46.0) | 81 (40.7) | ||
| 3 | 63 (10.5) | 38 (13.1) | 25 (8.0) | 42 (10.4) | 21 (10.6) | ||
| 4 | 37 (6.1) | 21 (7.2) | 16 (5.1) | 28 (6.9) | 9 (4.5) | ||
| Node metastasis, n, (%) | |||||||
| 0 | 445 (73.8) | 198 (68.0) | 247 (79.2) | .007 | 285 (70.5) | 160 (80.4) | .018 |
| 1 | 70 (11.6) | 41 (14.1) | 29 (9.3) | 57 (14.1) | 13 (6.5) | ||
| 2 | 81 (13.4) | 46 (15.8) | 35 (11.2) | 56 (13.9) | 25 (12.6) | ||
| 3 | 7 (1.2) | 6 (2.1) | 1 (0.3) | 6 (1.5) | 1 (0.5) | ||
| Pathological stage, n, (%) | |||||||
| I | 378 (62.7) | 164 (56.4) | 214 (68.6) | .010 | 241 (59.7) | 137 (68.8) | .089 |
| II | 106 (17.6) | 56 (19.2) | 50 (16.0) | 78 (19.3) | 28 (14.1) | ||
| III | 119 (19.7) | 71 (24.4) | 48 (15.4) | 85 (21.0) | 34 (17.1) | ||
| Adjuvant chemotherapy, n, (%) | |||||||
| Yes | 254 (42.1) | 117 (40.2) | 137 (43.9) | N.S. | 160 (39.6) | 94 (47.2) | N.S. |
| No | 349 (57.9) | 174 (59.8) | 175 (56.1) | 244 (60.4) | 105 (71.4) | ||
| EGFR mutation, n, (%) | |||||||
| Wild type | 478 (79.3) | 251 (86.3) | 227 (72.8) | <.001 | 329 (81.4) | 149 (74.9) | .069 |
| Mutant | 125 (20.7) | 40 (13.7) | 85 (27.2) | 75 (18.6) | 50 (25.1) | ||
| PD-L1%TPS | |||||||
| ≧1% | 223 (37.0) | 112 (38.49) | 111 (35.58) | N.S. | 141 (34.90) | 82 (41.21) | N.S. |
| <1% | 380 (63.0) | 179 (61.51) | 201 (64.42) | 263 (65.10) | 117 (58.79) | ||